Stockscreener 앱 받기
8.08
1.00%
0.08
시간 외 거래:
8.08
전일 마감가:
$8.00
열려 있는:
$7.94
하루 거래량:
691.28K
Relative Volume:
0.75
시가총액:
$418.31M
수익:
$742.90M
순이익/손실:
$52.60M
주가수익비율:
9.7408
EPS:
0.8295
순현금흐름:
$156.80M
1주 성능:
-0.62%
1개월 성능:
-26.48%
6개월 성능:
-1.58%
1년 성능:
+38.36%
1일 변동 폭
$7.85
$8.21
1주일 범위
$7.85
$8.44
52주 변동 폭
$4.02
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
명칭
Emergent Biosolutions Inc
전화
240-631-3200
주소
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
8.08 | 414.17M | 742.90M | 52.60M | 156.80M | 0.8295 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-03-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-08-29 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-04-10 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-10 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-04-29 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-11-08 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-05-05 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 개시 | The Benchmark Company | Buy |
| 2021-02-24 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-07-31 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-08-03 | 재확인 | Chardan Capital Markets | Buy |
| 2018-06-13 | 개시 | Argus | Buy |
| 2018-04-25 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2018-01-16 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Singular Research | Buy |
| 2016-04-15 | 개시 | Chardan Capital Markets | Buy |
| 2016-03-28 | 개시 | Singular Research | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2014-05-15 | 개시 | Summer Street Research | Buy |
| 2011-05-31 | 재확인 | WBB Securities | Strong Buy |
| 2011-01-10 | 재확인 | Wedbush | Outperform |
| 2010-11-05 | 재확인 | Wedbush | Outperform |
| 2010-08-18 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 재확인 | Caris & Company | Buy |
모두보기
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
Emergent BioSolutions signs contract modification award for CNJ-016 - MSN
Emergent BioSolutions authorizes $50 million stock repurchase program - MSN
U.S. Smallpox Treatment Market: See Incredible Growth - openPR.com
3 Vaccine Stocks Worth a Second Look as Mpox Is on the Rise in the U.S. - Barron's
Emergent BioSolutions outlines $720M–$760M 2026 revenue target as transformation plan advances - MSN
EBS Forecast, Price Target & Analyst Ratings | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
How The Investment Narrative For Emergent BioSolutions (EBS) Is Shifting After The $12 Target Reset - Yahoo Finance
BioThrax (Emergent BioSolutions) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F - Yahoo Finance
H.C. Wainwright cuts Emergent BioSolutions stock price target on revenue miss - Investing.com Nigeria
HC Wainwright Lowers Emergent Biosolutions (NYSE:EBS) Price Target to $12.00 - MarketBeat
EBS: HC Wainwright Lowers Price Target to $12, Maintains Buy Rat - GuruFocus
Macro Review: Is Emergent BioSolutions Inc currently under institutional pressure2026 Key Highlights & AI Powered Market Trend Analysis - baoquankhu1.vn
Market Catalysts: Is Emergent BioSolutions Inc. stock showing strong momentum2026 Snapshot & Comprehensive Market Scan Reports - baoquankhu1.vn
Emergent Biosolutions (NYSE:EBS) Cut to Hold at Wall Street Zen - MarketBeat
Why Emergent BioSolutions Inc. stock is favored by hedge funds2026 Geopolitical Influence & Entry Point Confirmation Signals - Naître et grandir
Sentiment Recap: Can Emergent BioSolutions Inc stock outperform in a bear marketEntry Point & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Emergent BioSolutions (NYSE: EBS) CFO reports unexercised option expirations - Stock Titan
Emergent BioSolutions (EBS) director granted 5,006 restricted stock units - Stock Titan
Emergent BioSolutions (NYSE: EBS) SVP awarded 44,834 stock options - Stock Titan
Emergent BioSolutions (EBS) CFO awarded 72,856 options, withholds 23,650 shares for taxes - Stock Titan
Emergent BioSolutions (EBS) EVP gets 44,834 options and 8,199 tax-withheld shares - Stock Titan
EBS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Emergent BioSolutions (EBS) SVP reports 116-share tax-withholding disposition - Stock Titan
Emergent BioSolutions (EBS) CFO logs 683-share tax-withholding disposition - Stock Titan
Emergent BioSolutions (EBS) EVP has 313 shares withheld for RSU taxes - Stock Titan
Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors - The Globe and Mail
Emergent BioSolutions announces appointment of John D. Fowler, Jr. to board of directors - marketscreener.com
Emergent BioSolutions Adds Independent Director Amid Turnaround Efforts - TipRanks
Emergent BioSolutions appoints John D. Fowler, Jr. as director and Audit and Finance Committee member - TradingView
John Fowler joins Emergent BioSolutions (NYSE: EBS) board, Audit role - Stock Titan
Emergent Biosolutions Announces Appointment Of John D. Fowler, Jr. To Board Of Directors - TradingView
Former Wells Fargo banker John Fowler joins Emergent BioSolutions board - Stock Titan
Emergent Biosolutions secures new contracts with Public Health Agency of Canada and Defence Department - Traders Union
Aug Levels: Is Emergent BioSolutions Inc stock showing strong momentumPortfolio Performance Summary & Accurate Intraday Trading Signals - baoquankhu1.vn
Q4 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Dow Dips Over 600 Points; US Producer Prices Increase In January - Sahm
Emergent BioSolutions Earnings: Revenue, Margins And GAAP Losses Paint Mixed Picture (EBS) - Seeking Alpha
Wall Street Zen Downgrades Emergent Biosolutions (NYSE:EBS) to Buy - MarketBeat
Emergent Biosolutions Q4 Earnings Call Highlights - MarketBeat
Emergent BioSolutions (EBS) One Off Loss Clouds Return To Profitability Narrative - simplywall.st
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Emergent BioSolutions (EBS) Stock Falls on Disappointing Revenue Guidance - GuruFocus
Emergent BioSolutions authorizes $50M stock buyback program By Investing.com - Investing.com India
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? - Stocktwits
Emergent BioSolutions Inc. (EBS): Investor Outlook Reveals 21.62% Potential Upside Amidst Challenging Revenue Growth - DirectorsTalk Interviews
Emergent BioSolutions Stock Pre-Market (-21%): Q4 Revenue Miss & Weak NARCAN Sales - Trefis
Emergent BioSolutions Inc (EBS) Q4 2025 Earnings Call Highlights: Strategic Gains Amid Revenue Challenges - GuruFocus
Emergent BioSolutions Inc. 2025 Q4ResultsEarnings Call Presentation (NYSE:EBS) 2026-02-26 - Seeking Alpha
Earnings call transcript: Emergent Biosolutions Misses Q4 2025 Expectations, Stock Edges Up - Investing.com Australia
Emergent Biosolutions: Q4 Earnings Snapshot - theheraldreview.com
Earnings call transcript: Emergent Biosolutions Misses Q4 2025 Expectations, Stock Edges Up By Investing.com - Investing.com South Africa
Emergent Biosolutions Inc (EBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.77%
자본화:
|
볼륨(24시간):